| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Min He, Niandong Zheng, Jing Zhang, Zhihong Hu, Guoliang You, Qingqing Ren, Hao Liu, Jianguo X. Growth hormone-secreting adenoma coexisted with gangliocytoma: a rare case. International journal of clinical and experimental pathology. vol 11. issue 7. 2020-03-25. PMID:31949764. |
we report a rare case of mixed gangliocytoma and growth hormone (gh)-secreting adenoma in a 50-year-old woman, who presented with acromegaly. |
2020-03-25 |
2023-08-13 |
Not clear |
| Kaori Hozumi, Hidenori Fukuoka, Yukiko Odake, Takehito Takeuchi, Tomoko Uehara, Takeshi Sato, Naoko Inoshita, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Yushi Hirota, Genzo Iguchi, Masaaki Taniguchi, Naoki Otsuki, Chikako Nishigori, Kenjiro Kosaki, Tomonobu Hasegawa, Wataru Ogawa, Yutaka Takahash. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. Endocrine journal. vol 66. issue 10. 2020-03-23. PMID:31189769. |
although acromegaly has been reported in patients with neurofibromatosis type 1 (nf1), these cases have not been associated with growth hormone (gh)-producing somatotroph adenoma, but with optic pathway glioma. |
2020-03-23 |
2023-08-13 |
Not clear |
| Kaori Hozumi, Hidenori Fukuoka, Yukiko Odake, Takehito Takeuchi, Tomoko Uehara, Takeshi Sato, Naoko Inoshita, Kenichi Yoshida, Ryusaku Matsumoto, Hironori Bando, Yushi Hirota, Genzo Iguchi, Masaaki Taniguchi, Naoki Otsuki, Chikako Nishigori, Kenjiro Kosaki, Tomonobu Hasegawa, Wataru Ogawa, Yutaka Takahash. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. Endocrine journal. vol 66. issue 10. 2020-03-23. PMID:31189769. |
acromegaly was suspected due to her facial features, and subsequent examinations revealed the presence of gh excess with a pituitary tumor, leading to the diagnosis of acromegaly. |
2020-03-23 |
2023-08-13 |
Not clear |
| Héléna Mosbah, Thierry Brue, Philippe Chanso. Annales d'endocrinologie. vol 80 Suppl 1. 2020-03-16. PMID:31606057. |
acromegaly is characterized by increased release of growth hormone (gh) and, consequently, insulin-like growth factor i (igf-i), most often by a pituitary adenoma. |
2020-03-16 |
2023-08-13 |
Not clear |
| Héléna Mosbah, Thierry Brue, Philippe Chanso. Annales d'endocrinologie. vol 80 Suppl 1. 2020-03-16. PMID:31606057. |
both gh and igf-i are currently biomarkers for assessing disease activity in patients with acromegaly. |
2020-03-16 |
2023-08-13 |
Not clear |
| Kosuke Mukai, Michio Otsuki, Daisuke Tamada, Tetsuhiro Kitamura, Reiko Hayashi, Aya Saiki, Yuko Goto, Hideyuki Arita, Satoru Oshino, Eiichi Morii, Youichi Saitoh, Iichiro Shimomur. Clinical Characteristics of Acromegalic Patients With Paradoxical GH Response to Oral Glucose Load. The Journal of clinical endocrinology and metabolism. vol 104. issue 5. 2020-02-27. PMID:30476255. |
a paradoxical gh response to oral glucose (og) is often found in acromegaly. |
2020-02-27 |
2023-08-13 |
Not clear |
| Kosuke Mukai, Michio Otsuki, Daisuke Tamada, Tetsuhiro Kitamura, Reiko Hayashi, Aya Saiki, Yuko Goto, Hideyuki Arita, Satoru Oshino, Eiichi Morii, Youichi Saitoh, Iichiro Shimomur. Clinical Characteristics of Acromegalic Patients With Paradoxical GH Response to Oral Glucose Load. The Journal of clinical endocrinology and metabolism. vol 104. issue 5. 2020-02-27. PMID:30476255. |
however, the clinical characteristics of patients with acromegaly and a paradoxical gh response to og (og responders) remain unclear. |
2020-02-27 |
2023-08-13 |
Not clear |
| Pietro Maffei, Francesca Dassie, Alexandra Wennberg, Matteo Parolin, Roberto Vetto. The Endothelium in Acromegaly. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:31396153. |
acromegaly, a condition of chronic gh and igf-1 hypersecretion, is frequently associated to cardiovascular complications, although recent studies have shown a reduction in the prevalence of these comorbidities in well-controlled patients and a mortality risk similar to normal aging population. |
2020-02-25 |
2023-08-13 |
Not clear |
| Pietro Maffei, Francesca Dassie, Alexandra Wennberg, Matteo Parolin, Roberto Vetto. The Endothelium in Acromegaly. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:31396153. |
in conclusion, the pathophysiology of endothelial dysfunction in the condition of gh and igf-1 excess remains a crucial area of investigation to fully dissect the association of acromegaly with cardiovascular disease complications. |
2020-02-25 |
2023-08-13 |
Not clear |
| Greisa Vila, Jens Otto L Jørgensen, Anton Luger, Günter K Stall. Insulin Resistance in Patients With Acromegaly. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:31417493. |
acromegaly is characterized by chronic overproduction of growth hormone (gh) that leads to insulin resistance, glucose intolerance and, ultimately, diabetes. |
2020-02-25 |
2023-08-13 |
Not clear |
| Greisa Vila, Jens Otto L Jørgensen, Anton Luger, Günter K Stall. Insulin Resistance in Patients With Acromegaly. Frontiers in endocrinology. vol 10. 2020-02-25. PMID:31417493. |
in the present review, we elucidate the effects of gh hypersecretion on metabolic organs, describing the pathophysiology of impaired glucose tolerance in acromegaly, as well as the impact of acromegaly-specific therapies on glucose metabolism. |
2020-02-25 |
2023-08-13 |
Not clear |
| Laila Füchtbauer, Daniel S Olsson, Eva C Coopmans, Bengt-Åke Bengtsson, Lise-Lott Norrman, Sebastian J C M M Neggers, Ann Hellström, Gudmundur Johannsso. Increased number of retinal vessels in acromegaly. European journal of endocrinology. vol 182. issue 3. 2020-02-17. PMID:31917679. |
excess of growth hormone (gh) and insulin-like growth factor 1 (igf-1), as in acromegaly, is associated with increased risk of diabetes, but whether retinal vessels are altered is unknown. |
2020-02-17 |
2023-08-13 |
Not clear |
| Gherardo Mazziotti, Andrea G A Lania, Ernesto Canali. MANAGEMENT OF ENDOCRINE DISEASE: Bone disorders associated with acromegaly: mechanisms and treatment. European journal of endocrinology. vol 181. issue 2. 2020-02-06. PMID:31100715. |
indeed, acromegaly causes skeletal fragility, and vertebral fractures are reported in a remarkable number of subjects exposed to gh and igf-i excess. |
2020-02-06 |
2023-08-13 |
human |
| N N Molitvoslovova, L Y Rozhinskaya, G A Melnichenk. [Russian consensus on the diagnosis, treatment, and monitoring of acromegalia (draft)]. Problemy endokrinologii. vol 53. issue 4. 2020-01-08. PMID:31627523. |
acromegaly is a serious disease of the hypothalamic-pituitary system, caused by chronic overproduction of growth hormone (gh) in individuals with completed physiological growth, affecting mainly people of working age. |
2020-01-08 |
2023-08-13 |
human |
| V V Vak. [Drug therapy for acromegaly]. Problemy endokrinologii. vol 51. issue 2. 2020-01-08. PMID:31627555. |
acromegaly is a severe disease caused by excessive secretion of growth hormone (gh), usually a pituitary tumor (98%), which in turn leads to a significant increase in the production of insulin-like growth factor 1 (igf-1) by the liver, which mainly determines the tissue effect of gh.the larger the size of the tumor, the more it produces gh and the less likely it is to achieve adequate control of hormonal secretion. |
2020-01-08 |
2023-08-13 |
Not clear |
| V V Vak. [Drug therapy for acromegaly]. Problemy endokrinologii. vol 51. issue 2. 2020-01-08. PMID:31627555. |
large tumors that extend beyond the sella turcica are found in 70-80% of patients with acromegaly and present the greatest difficulties for successful treatment.increased secretion of gh and igf-1 gives adverse systemic, metabolic and, possibly, neoplastic effects, which reduces the life expectancy of patients with acromegaly and increases the mortality rate by 2-3 times. |
2020-01-08 |
2023-08-13 |
Not clear |
| I A Ilovaiskaya, N N Molivosbvova, Y I Marova, L K Dzeranova, S D Arapova, L I Astafyeva, B A Kadashev, G A Melntchenk. [Drug treatment for acromegaly: results of long-term use of Sandostatin LAR]. Problemy endokrinologii. vol 52. issue 4. 2020-01-08. PMID:31627642. |
То evaluate the effectiveness and safety of drug treatment for acromegaly, the authors conducted an open-labeled prospective study of the impact of treatment with long-acting octreotide sandostatm lar) on the content of growth hormone (gh) and irf-1 and on the size of a pituitary tumor. |
2020-01-08 |
2023-08-13 |
Not clear |
| I A Ilovaiskaya, N N Molivosbvova, Y I Marova, L K Dzeranova, S D Arapova, L I Astafyeva, B A Kadashev, G A Melntchenk. [Drug treatment for acromegaly: results of long-term use of Sandostatin LAR]. Problemy endokrinologii. vol 52. issue 4. 2020-01-08. PMID:31627642. |
the findings suggest that treatment with sandostatin lar in a dose of 20 mg is an effective and safe treatment, leads to a significant reduction in the values of gh and il gf-1 just 3 months after treatment, and controls hormonal secretion and tumor growth in most patients with acromegaly. |
2020-01-08 |
2023-08-13 |
Not clear |
| Colin P S Kruse, David A Cottrill, John J Kopchic. Could calgranulins and advanced glycated end products potentiate acromegaly pathophysiology? Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 46-47. 2020-01-06. PMID:31071497. |
while current treatment modalities have greatly improved prognoses for most patients, a significant number present clinical symptoms of acromegaly with elevated levels of igf-1 in the absence of increased gh levels, a phenomenon known as micromegaly. |
2020-01-06 |
2023-08-13 |
human |
| Leila Moradi, Fatemeh Amiri, Hajieh Shahbazia. Insulin resistance and pseudoacromegaly: A case report. Diabetes & metabolic syndrome. vol 13. issue 2. 2019-12-27. PMID:31336543. |
metabolic and somatic features of acromegaly caused by high serum concentrations of insulin-like growth factor-i (igf-i) and excess growth hormone (gh) production. |
2019-12-27 |
2023-08-13 |
Not clear |